SLC38A2 and neoplasm: Although many studies have confirmed that blocking glutamine metabolism pathways significantly inhibits tumor progression, research and targeted drugs specifically for SLC38A2 remain limited (Wang et al., 2024; Li et al., 2023d; Jin et al., 2023).